Alvarado-Gutiérrez AY, Hernández-Franco J, Sánchez-Villavicencio I

Language: Spanish
References: 26
Page: 174-181
PDF size: 291.16 Kb.

ABSTRACT

Drooling is defined as excess saliva in the mouth that exceeds the margin of the lips. The injection of botulinum toxin type A appears to be the safest as it offers a range of effectiveness up to 3 months. Objectives: To study whether low (75 units) of abobotoxina type in the parotid gland of patients with Parkinson’s disease and drooling, dose is effective without the presence of adverse effects. Methods: cross-sectional study in patients with drooling scale clinical scale for Parkinson disease (SCS-PD), severity and frequency of salivation (DSFS), at the time of study entry and at weeks 1, 2, 4 , 8, 12, 16. Results: 6 patients were included in the study, with a mean age of 67.3 years, 11.8 years on average for developing Parkinson’s four years of suffering drooling. Analysis of decreasing an overall score for SCS-PD from baseline to week 12, presents statistical significance (p = 0.0030) thus corroborating the beneficial effect of the toxin for at least 3 months. Conclusions: a dose of 75 units abobotoxina type A appears to be suitable for symptom control without creating undesirable side effects start from the first week of the application keeping up to 3 months after starting treatment.

REFERENCES

1. Amanda Amrita Lakraj, Narges Moghimi, Bahman Jabbari. Sialorrhea: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. Toxins 2013; 5: 1010-31.

2. Hamdy S, Aziz Q, Rothwell JC, Hobson A, Barlow J, et al. Cranial ner ve modulation of human cor tical swallowing motor pathways. Am J Physiol 1997; 272: G802-G808.

3. Volonte MA, Por ta M, Comi G. Clinical assessment of dysphagia in early phases of parkinson’s disease. Neurol Sci 2002;23:S121-S122.

4. Glickman S, Deaney CN. Treatment of relative sialorrhoea with botulinum toxin type a: Description and rationale for an injection procedure with case report. Eur J Neurol 2001; 8, 567-71.

5. Hung CC, Fu PK, Wang HY, Chan CH, Lan TH. Treatment effects of traditional Chinese medicines suoquan pill and wuling powder on clozapine-induced hypersalivation in patients with schizophrenia: study protocol of a randomized, placebocontrolled trial. J Chin Integr Med 2011; (9): 495-502.

6. Scully C, Limeres J, Gleeson M, Tomás I, Diz P. Drooling. J Oral Pathol Med 2009; 38: 321-7.

7. Holsinger FC, Bui DT. Anatomy, function, and evaluation of the salivary glands. Salivary. Glands Disorders 2007; 1:1-16.

8. Hollinshead WH. Anatomy for Surgeons; Hoeber Medical Division, Harper and Row: New York, NY, USA, 1968; 551-6.

9. Garrett JR, Proctor GB. Control of salivation. In the scientific basis of eating: taste and smell, salivation, mastication and swallowing and their dysfunctions; frontiers of oral biology; linden, D., Roger, W.A., Eds.; Karger: Basel, Switzerland, 1998;135-55.

10. Myer CM., 3rd. Sialorrhea. Pediatr Clin North Am 1989; 36:1495-500.

11. Borg M, Hirst F. The role of radiation therapy in the management of sialorrhea. Int J Radiat Oncol Biol Phys 1998; 41: 1113-9.

12. Lloret SP, Nano G, Carosella A, Gamzu E, Merello M. A doubleblind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the shor t-term relief of sialorrhea symptoms in parkinson’s disease patients. J. Neurol. Sci. 2011, 310, 248–250.

13. Mato, A, Limeres J, Tomas I, Muñoz M, Abuin C, Feijoo JF, et al. Management of drooling in disabled patients with scopolamine patches. Br. J. Clin. Pharmacol 69, 684–688.

14. Crysdale, W.S. Management options for the drooling patient. Ear Nose Throat J. 1989:68:820, 825-6, 829-30.

15. Lim EC, Seet RC. Use of botulinum toxin in the neurology clinic. Nat Rev Neurol 2010;6:624-36.

16. Thomsen TR, Galpern WR, Asante A, Arenovich T, Fox SH. Ipratropium bromide spray as treatment for sialorrhea in Parkinson’s disease. Mov Disord 2007; 22:2268-73.

17. Pal PK, Calne DB, Calne S, Tsui JK. Botulinum toxin a as treatment for drooling saliva in pd. Neurology 2000;54,244-7.

18. Ondo WG, Hunter C, Moore W. A double-blind placebocontrolled trial of botulinum toxin B for sialorrhea in parkinson’s disease. Neurol 2004;62:37-40.

19. Jackson CE, Gronseth G, Rosenfeld J, Barohn RJ, Dubinsky R, et al. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve 2009; 39, 137-43.

20. Lagalla, G, Millevolte M, Capecci M, Provinciali L, Ceravolo G. Botulinum toxin type A for drooling in parkinson’s disease: A double-blind, randomized, placebo-controlled study. Mov Disord 2006; 21, 704-7.

21. Chinnapongse, R, Gullo K, Nemeth P, Zhang P, Griggs L. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson’s disease: A prospective doubleblind trial. Mov Disord 2012;27:219-26.

22. Lipp AT, Trottenberg, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin a for treatment of drooling. Neurology 2003;61:1279-81.

23. Wilken B, Aslami B; Backes H. Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B. Neuropediatrics 2008;39:200-4.

24. Guidubaldi, A, Fasano A, Ialongo T, Piano C, Pompili M, et al. Botulinum toxin a versus b in sialorrhea: A prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or parkinson’s disease. Mov Disord 2011;26,313-9.

25. Alrefai AH, Aburahma SK, Khader YS. Treatment of sialorrhea in children with cerebral palsy: A double-blind placebo controlled trial. Clin Neurol. Neurosurg 2009; 111, 79-82.

26. Perez Lloret S, Pirán Arce G, Rossi M, Caivano Nemet ML, Salsamendi P, et al. Validation of a new scale for the evaluation of sialorrhea in patients with Parkinson’s disease. Mov Disord 2007; 22:107-11.